Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: The role of aldehyde dehydrogenase

Pharmacological Reviews

Volumn 59, Issue 2, 2007, Pages 125-150

  Marchitti, Satori A ^a   Deitrich, Richard A ^a   Vasiliou, Vasilis ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; 3,4 DIHYDROXYPHENYLGLYCOLALDEHYDE; ACETALDEHYDE; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE INHIBITOR; ALDEHYDE REDUCTASE; ARYL SULFOTRANSFERASE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE DERIVATIVE; DAIDZEIN; DISULFIRAM; FREE RADICAL; GLUCURONOSYLTRANSFERASE; ISOQUINOLINE; LEVODOPA; ROTENONE; SALSOLINOL; TETRAHYDROPAPAVEROLINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; BINDING AFFINITY; BIOTRANSFORMATION; CATALYSIS; CELL DEATH; CELL DIFFERENTIATION; CELL STRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CYTOSOL; CYTOTOXICITY; DEGENERATIVE DISEASE; DNA DAMAGE; DNA REPAIR; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; ELECTRON SPIN RESONANCE; GLUCURONIDATION; HUMAN; HYPERPROLINEMIA; HYPOTHALAMUS; MEDULLA OBLONGATA; MITOCHONDRION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN LARSSON SYNDROME; SUBSTANTIA NIGRA; SYNAPTOSOME; VENTRAL TEGMENTUM;

3,4-DIHYDROXYPHENYLACETIC ACID; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALDEHYDE REDUCTASE; ALDEHYDES; ANIMALS; APOPTOSIS; ARYLSULFOTRANSFERASE; BIOLOGICAL TRANSPORT; BRAIN; CATECHOL O-METHYLTRANSFERASE; FREE RADICALS; GLUCURONOSYLTRANSFERASE; HUMANS; NEURONS;

EID: 34249794888     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.59.2.1     Document Type: Review

References (262)

1. Agarwal DP, Hafer G, Harada S, and Goedde HW (1982) Studies on aldehyde dehydrogenase and aldehyde reductase in human brain. Prog Clin Biol Res 114:319-327.
2. AmbroziakWand Pietruszko R (1987) Human aldehyde dehydrogenase: metabolism of putrescine and histamine. Alcohol Clin Exp Res 11:528-532.
3. Ambroziak W and Pietruszko R (1991) Human aldehyde dehydrogenase: activity with aldehyde metabolites of monoamines, diamines, and polyamines. J Biol Chem 266:13011-13018.
4. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, and Agid Y (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12:25-31.
5. Axelrod J and Tomchick R (1958) Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 233:702-705.
6. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, and Sablin SO (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 993:334-344.
7. Basu AK, O'Hara SM, Valladier P, Stone K, Mols O, and Marnett LJ (1988) Identification of adducts formed by reaction of guanine nucleosides with malondialdehyde and structurally related aldehydes. Chem Res Toxicol 1:53-59.
8. 1-pyrroline-5-carboxylate synthase. Hum Mol Genet 9:2853-2858.
9. -1-Pyrroline-5-carboxylate synthase deficiency: neurodegeneration, cataracts and connective tissue manifestations combined with hyperammonaemia and reduced ornithine, citrulline, arginine and proline. Eur J Pediatr 164:31-36.
10. Beisswenger TB, Holmquist B, and Vallee BL (1985) -χ-ADH is the sole alcohol dehydrogenase isozyme of mammalian brains: implications and inferences. Proc Natl Acad Sci USA 82:8369-8373.
11. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
12. Blaschko H (1952) Amine oxidase and amine metabolism. Pharmacol Rev 4:415-458.
13. Bondareff W, Mountjoy CQ, and Roth M (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 32:164-168.
14. Bonnet JJ, Legros H, Janin F, Dourmap N, and Costentin J (2004) Assessment of the in vitro and in vivo toxicity of 3,4- dihydroxyphenylacetaldehyde (DOPAL). Ann Pharm Fr 62:323-331.
15. Boobis AR, Murray S, Jones DH, Reid JL, and Davies DS (1980) Urinary conjugates of 4-hydroxy-3-methoxyphenylethylene glycol do not provide an index of brain amine turnover in man. Clin Sci (Lond) 58:311-316.
16. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, and Jansen PL (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-17964.
17. Boyer CS and Petersen DR (1991) The metabolism of 3,7-dimethyl-2,6- Octadienal (citral) in rat hepatic mitochondrial and cytosolic fractions: interactions with aldehyde and alcohol dehydrogenases. Drug Metab Dispos 19:81-86.
18. Breese GR, Chase TN, and Kopin IJ (1969) Metabolism of some phenylethylamines and their β-hydroxylated analogs in brain. J Pharmacol Exp Ther 165:9-13.
19. Brooks PJ and Theruvathu JA (2005) DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol 35:187-193.
20. Brooks WJ, Jarvis MF, and Wagner GC (1989) Astrocytes as a primary locus for the conversion MPTP into MPP+. J Neural Transm 76:1-12.
21. Burke WJ, Chung HD, and Li SW (1999a) Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography. Anal Biochem 273:111-116.
22. Burke WJ, Franko MW, Chung HD, Kumar VB, and Galvin JE (2006) DOPAL, the MAO metabolite of dopamine, triggers aggregation of α-synuclein in vitro: mechanism in PD pathogenesis. In press.
23. Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, and Nixon RA (1994) Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease. Brain Res 661:35-42.
24. Burke WJ, Kristal BS, Yu BP, Li SW, and Lin TS (1998) Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Res 787:328-332.
25. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA, et al. (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25:101-115.
26. Burke WJ, Li SW, Schmitt CA, Xia P, Chung HD, and Gillespie KN (1999b) Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death. Brain Res 816:633-637.
27. Burke WJ, Li SW, Schmitt CA, Zahm DS, Chung HD, Conway AD, Conway AD, Lampe P, Johnson EM, Lin TS, et al. (2000) Catecholamine-derived aldehyde neurotoxins, in Neurotoxic Factors in Parkinson's Disease and Related Disorders (Storch A and Collins MA eds) pp 167-180, Kluwer Academic Publishers, New York.
28. Burke WJ, Li SW, Williams EA, Nonneman R, and Zahm DS (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 989:205-213.
29. Burke WJ, Li SW, Zahm DS, Macarthur H, Kolo LL, Westfall TC, Anwar M, Glickstein SB, and Ruggiero DA (2001) Catecholamine monoamine oxidase a metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res 891:218-227.
30. Burke WJ, Schmitt CA, Gillespie KN, and Li SW (1996) Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells. Brain Res 722:232-235.
31. Burke WJ, Schmitt CA, Li SW, Gillespie KN, Park DH, and Joh TH (1995) Simultaneous measurement of enzyme activity, protein, mRNA, and metabolites in small samples. Anal Biochem 230:345-348.
32. Burke WJ, Schmitt CA, Miller C, and Li SW (1997) Norepinephrine transmitter metabolite induces apoptosis in differentiated rat pheochromocytoma cells. Brain Res 760:290-293.
33. Cantuti-Castelvetri I and Joseph JA (1999) Differential effect of dopamine catabolism and uptake inhibition on dopamine-induced calcium dysregulation and viability loss. Free Radic Biol Med 27:1393-1404.
34. Cassarino DS and Bennett JP Jr (1999) An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 29:1-25.
35. Chambliss KL and Gibson KM (1992) Succinic semialdehyde dehydrogenase from mammalian brain: subunit analysis using polyclonal antiserum. Int J Biochem 24:1493-1499.
36. Chao YC, Liou SR, Chung YY, Tang HS, Hsu CT, Li TK, and Yin SJ (1994) Polymorphism of alcohol and aldehyde dehydrogenase genes and alcoholic cirrhosis in Chinese patients. Hepatology 19:360-366.
37. Chen JJ and Yu BP (1996) Detoxification of reactive aldehydes in mitochondria: effects of age and dietary restriction. Aging (Milano) 8:334-340.
38. Chio KS and Tappel AL (1969) Inactivation of ribonuclease and other enzymes by peroxidizing lipids and by malonaldehyde. Biochemistry 8:2827-2832.
39. Cleeter MW, Cooper JM, and Schapira AH (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58:786-789.
40. Cohen G (1976) Alkaloid products in the metabolism of alcohol and biogenic amines. Biochem Pharmacol 25:1123-1128.
41. Cohen G, Farooqui R, and Kesler N (1997) Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci USA 94:4890-4894.
42. Cohen G and Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249:2447-2452.
43. Colzi A, Musolino A, Iuliano A, Fornai F, Bonuccelli U, and Corsini GU (1996) Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite in in vivo dialysate from rat striatum. J Neurochem 66:1510-1517.
44. Craddock N, Owen MJ, and O'Donovan MC (2006) The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol Psychiatry 11:446-458.
45. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, and Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816-830.
46. Davis VE, Brown H, Huff JA, and Cashaw JL (1967) Ethanol-induced alterations of norepinephrine metabolism in man. J Lab Clin Med 69:787-799.
47. Davis VE and Walsh MJ (1970) Alcohol, amines, and alkaloids: a possible biochemical basis for alcohol addiction. Science (Wash DC) 167:1005-1007.
48. Davis VE, Walsh MJ, and Yamanaka Y (1970) Augmentation of alkaloid formation from dopamine by alcohol and acetaldehyde in vitro. J Pharmacol Exp Ther 174:401-412.
49. Deak KL, Dickerson ME, Linney E, Enterline DS, George TM, Melvin EC, Graham FL, Siegel DG, Hammock P, Mehltretter L, et al. (2005) Analysis of ALDH1A2, CYP26A1, CYP26B1, CRABP1, and CRABP2 in human neural tube defects suggests a possible association with alleles in ALDH1A2. Birth Defects Res A Clin Mol Teratol 73:868-875.
50. Dedek J, Baumes R, Tien-Duc N, Gomeni R, and Korf J (1979) Turnover of free and conjugated (sulphonyloxy) dihydroxyphenylacetic acid and homovanillic acid in rat striatum. J Neurochem 33:687-695.
51. Deitrich RA and Erwin VG (1975) Involvement of biogenic amine metabolism in ethanol addiction. Fed Proc 34:1962-1968.
52. Destaillats H, Spaulding RS, and Charles MJ (2002) Ambient air measurement of acrolein and other carbonyls at the Oakland-San Francisco Bay Bridge toll plaza. Environ Sci Technol 36:2227-2235.
53. Duester G, Farres J, Felder MR, Holmes RS, Hoog JO, Pares X, Plapp BV, Yin SJ, and Jornvall H (1999) Recommended nomenclature for the vertebrate alcohol dehydrogenase gene family. Biochem Pharmacol 58:389-395.
54. Duncan RJ and Sourkes TL (1974) Some enzymic aspects of the production of oxidized or reduced metabolites of catecholamines and 5-hydroxytryptamine by brain tissues. J Neurochem 22:663-669.
55. Dupe V, Matt N, Garnier JM, Chambon P, Mark M, and Ghyselinck NB (2003) A newborn lethal defect due to inactivation of retinaldehyde dehydrogenase type 3 is prevented by maternal retinoic acid treatment. Proc Natl Acad Sci USA 100:14036-14041.
56. Eisenhofer G, Aneman A, Hooper D, Rundqvist B, and Friberg P (1996a) Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 66:1565-1573.
57. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO 3rd, Quyyumi AA, Lambert G, Chin J, Jennings GL, and Goldstein DS (1992) Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 85:1775-1785.
58. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, and Esler MD (1996b) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667-1676.
59. Eisenhofer G, Kopin IJ, and Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331-349.
60. Eisenhofer G, Lamensdorf I, Kirk K, Kawamura M, and Sato S (2000) Oxidative deamination of monoamines and biogenic aldehydes in neurodegeneration, in Role of Quinone Species in Cellular Toxicity (Creveling CR ed) pp 103-145, F. P. Graham, Johnson City, TN.
61. Eisenhofer G, Rundqvist B, and Friberg P (1998) Determinants of cardiac tyrosine hydroxylase activity during exercise-induced sympathetic activation in humans. Am J Physiol 274:R626-R634.
62. Enomoto N, Takase S, Takada N, and Takada A (1991) Alcoholic liver disease in heterozygotes of mutant and normal aldehyde dehydrogenase-2 genes. Hepatology 13:1071-1075.
63. Erwin VG and Deitrich RA (1966) Brain aldehyde dehydrogenase. localization, purification, and properties. J Biol Chem 241:3533-3539.
64. Erwin VG, Kim J, and Anderson AD (1975) Effects of aldehydes on sodium plus potassium ion-stimulated adenosine triphosphatase of mouse brain. Biochem Pharmacol 24:2089-2095.
65. Esterbauer H (1993) Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 57:779S-785S.
66. Esterbauer H, Schaur RJ, and Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128.
67. Esterbauer H, Zollner H, and Scholz N (1975) Reaction of glutathione with conjugated carbonyls. Z Naturforsch [C] 30:466-473.
68. Fan X, Molotkov A, Manabe S, Donmoyer CM, Deltour L, Foglio MH, Cuenca AE, Blaner WS, Lipton SA, and Duester G (2003) Targeted disruption of Aldh1a1 (Raldh1) provides evidence for a complex mechanism of retinoic acid synthesis in the developing retina. Mol Cell Biol 23:4637-4648.
69. 6 deficiency and seizures in hyperprolinemia type II. J Biol Chem 276:15107-15116.
70. Feng Z, Hu W, and Tang MS (2004) Trans-4-hydroxy-2-nonenal inhibits nucleotide excision repair in human cells: a possible mechanism for lipid peroxidation-induced carcinogenesis. Proc Natl Acad Sci USA 101:8598-8602.
71. Fiskum G, Starkov A, Polster BM, and Chinopoulos C (2003) Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann NY Acad Sci 991:111-119.
72. Floor E, Leventhal PS, Wang Y, Meng L, and Chen W (1995) Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurochem 64:689-699.
73. Florang VR, Rees JN, Brogden NK, Anderson DG, Hurley TD, and Doorn JA (2007) Inhibition of the oxidative metabolism of 3,4- dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology 28:76-82.
74. Fornai F, Giorgi FS, Bassi L, Ferrucci M, Alessandri MG, and Corsini GU (2000) Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment. Brain Res 861:126-134.
75. Fowler CJ and Benedetti MS (1983) The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. J Neurochem 40:1534-1541.
76. Gabbay KH and Cathcart ES (1974) Purification and immunologic identification of aldose reductases. Diabetes 23:460-468.
77. Gai WP, Geffen LB, Denoroy L, and Blessing WW (1993) Loss of C1 and C3 epinephrine-synthesizing neurons in the medulla oblongata in Parkinson's disease. Ann Neurol 33:357-367.
78. Galter D, Buervenich S, Carmine A, Anvret M, and Olson L (2003a) ALDH1 MRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis 14:637-647.
79. Galter D, Carmine A, Buervenich S, Duester G, and Olson L (2003b) Distribution of class I, III and IV alcohol dehydrogenase mRNAs in the adult rat, mouse and human brain. Eur J Biochem 270:1316-1326.
80. Gibson KM, Hoffmann GF, Hodson AK, Bottiglieri T, and Jakobs C (1998) 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics 29:14-22.
81. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, Bhatia K, Chen LZ, Fang B, Lisker R, et al. (1992) Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 88:344-346.
82. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, and Kopin IJ (1988) Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Investig 81:213-220.
83. Goto K, Mochizuki H, Hattori T, Nakamura N, and Mizuno Y (1997) Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture. Brain Res 754:260-268.
84. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
85. Grimm J, Mueller A, Hefti F, and Rosenthal A (2004) Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci USA 101:13891-13896.
86. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
87. Hafer G, Agarwal DP, and Goedde HW (1987) Human brain aldehyde dehydrogenase: activity with DOPAL and isozyme distribution. Alcohol 4:413-418.
88. Halbrugge T, Wolfel R, and Graefe KH (1989) Plasma 3,4- dihydroxyphenylglycol as a tool to assess the role of neuronal uptake in the anaesthetized rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 340:726-732.
89. Harada S, Agarwal DP, and Goedde HW (1978) Isozyme variations in acetaldehyde dehydrogenase (E.C. 1.2.1.3) in human tissues. Hum Genet 44:181-185.
90. Harada S, Agarwal DP, and Goedde HW (1982) Human aldehyde dehydrogenase: 3,4-dihydroxyphenylaldehyde metabolizing isozymes. Prog Clin Biol Res 114:147-153.
91. Hasegawa T, Matsuzaki-Kobayashi M, Takeda A, Sugeno N, Kikuchi A, Furukawa K, Perry G, Smith MA, and Itoyama Y (2006) α-Synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease. FEBS Lett 580:2147-2152.
92. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, and Masliah E (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 10:717-721.
93. 2+-independent mechanism. Brain Res 931:96-99.
94. Helander A and Tottmar O (1989) Reactions of biogenic aldehydes with hemoglobin. Alcohol 6:71-75.
95. Henchcliffe C, Schumacher HC, and Burgut FT (2005) Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother 5:811-821.
96. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, et al. (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21:3017-3023.
97. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, and Agid Y (1997) Neuronal vulnerability in Parkinson's disease. J Neural Transm Suppl 50:79-88.
98. Hoog JO, Hedberg JJ, Stromberg P, and Svensson S (2001) Mammalian alcohol dehydrogenase - functional and structural implications. J Biomed Sci 8:71-76.
99. Horio M, Ito A, Matsuoka Y, Moriyama T, Orita Y, Takenaka M, and Imai E (2001) Apoptosis induced by hypertonicity in Madin Darley canine kidney cells: protective effect of betaine. Nephrol Dial Transplant 16:483-490.
100. Isse T, Oyama T, Kitagawa K, Matsuno K, Matsumoto A, Yoshida A, Nakayama K, Nakayama K, and Kawamoto T (2002) Diminished alcohol preference in transgenic mice lacking aldehyde dehydrogenase activity. Pharmacogenetics 12:621-626.
101. Javitch JA, D'Amato RJ, Strittmatter SM, and Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
102. Jeffery DR and Roth JA (1984) Characterization of membrane-bound and soluble catechol-o-methyltransferase from human frontal cortex. J Neurochem 42:826-832.
103. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, and Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95:4029-4034.
104. Ka H, Park HJ, Jung HJ, Choi JW, Cho KS, Ha J, and Lee KT (2003) Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett 196:143-152.
105. Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, Kitamura S, Namekata K, Miki T, and Ohta S (2000) Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem Biophys Res Commun 273:192-196.
106. Karoum F, Moyer-Schwing J, Potkin SG, and Wyatt RJ (1977) Presence of free, sulfate and glucuronide conjugated 3-methoxy-4-Hydroxyphenylglycol (MHPG) in human brain, cerebrospinal fluid and plasma. Brain Res 125:333-339.
107. Kawamura M, Eisenhofer G, Kopin IJ, Kador PF, Lee YS, Tsai JY, Fujisawa S, Lizak MJ, Sinz A, and Sato S (1999) Aldose reductase, a key enzyme in the oxidative deamination of norepinephrine in rats. Biochem Pharmacol 58:517-524.
108. Kawamura M, Kopin IJ, Kador PF, Sato S, Tjurmina O, and Eisenhofer G (1997) Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J Auton Nerv Syst 66:145-148.
109. Kelson TL, Secor M Jr, and Rizzo WB (1997) Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochim Biophys Acta 1335:99-110.
110. Keung WM (2001) Biogenic aldehyde(s) derived from the action of monoamine oxidase may mediate the antidipsotropic effect of daidzin. Chem-Biol Interact 130-132:919-930.
111. Kim YM, Kim MN, Lee JJ, and Lee MK (2005) Inhibition of dopamine biosynthesis by tetrahydropapaveroline. Neurosci Lett 386:1-4.
112. Kluck RM, Bossy-Wetzel E, Green DR, and Newmeyer DD (1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Wash DC) 275:1132-1136.
113. Kopin IJ (1964) Storage and metabolism of catecholamines: the role of monoamine oxidase. Pharmacol Rev 16:179-191.
114. Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37:333-364.
115. 3 released by tyramine and reserpine. J Pharmacol Exp Ther 138:351-359.
116. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, and Burke WJ (2001) Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 30:924-931.
117. Kristal BS, Park BK, and Yu BP (1996) 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem 271:6033-6038.
118. 6- methylguanine-DNA methyltransferase by various aldehydes in cultured human bronchial fibroblasts. Carcinogenesis 6:1755-1759.
119. Kumagai T, Kawamoto Y, Nakamura Y, Hatayama I, Satoh K, Osawa T, and Uchida K (2000) 4-Hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem Biophys Res Commun 273:437-441.
120. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, and Kopin IJ (2000a) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 60:552-558.
121. Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, and Kopin IJ (2000b) 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 868:191-201.
122. Lang AE and Lozano AM (1998) Parkinson's disease: first of two parts. N Engl J Med 339:1044-1053.
123. Laplane D, Attal N, Sauron B, de BA, and Dubois B (1992) Lesions of basal ganglia due to disulfiram neurotoxicity. J Neurol Neurosurg Psychiatry 55:925-929.
124. Lassen N, Bateman JB, Estey T, Kuszak JR, Piatigorsky J, Duester G, and Vasiliou V (2006) Cataract phenotype in Aldh1a1-/-/Aldh3a1-/- double knockout mice. The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; 2006 Apr 30-May 4; Ft. Lauderdale, FL. Invest Ophthalmol Vis Sci E-Abstract 4105.
125. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, and Wisniewski HM (1995) Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (Berl) 89:35-41.
126. Lee FJ, Liu F, Pristupa ZB, and Niznik HB (2001) Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15:916-926.
127. Lee MJ, Elberling JA, and Nagasawa HT (1992) N1-hydroxylated derivatives of chlorpropamide and its analogs as inhibitors of aldehyde dehydrogenase in vivo. J Med Chem 35:3641-3647.
128. Lee VM, Balin BJ, Otvos L Jr, and Trojanowski JQ (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science (Wash DC) 251:675-678.
129. Legros H, Dingeval MG, Janin F, Costentin J, and Bonnet JJ (2004a) Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 25:365-375.
130. Legros H, Janin F, Dourmap N, Bonnet JJ, and Costentin J (2004b) Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones. J Neurosci Res 75:429-435.
131. Leonarduzzi G, Robbesyn F, and Poli G (2004) Signaling kinases modulated by 4-hydroxynonenal. Free Radic Biol Med 37:1694-1702.
132. Li SW, Lin TS, Minteer S, and Burke WJ (2001) 3,4- Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Brain Res Mol Brain Res 93:1-7.
133. Lindahl R (1992) Aldehyde dehydrogenases and their role in carcinogenesis. Crit Rev Biochem Mol Biol 27:283-335.
134. Liu J and Mori A (1993) Monoamine metabolism provides an antioxidant defense in the brain against oxidant- and free radical-induced damage. Arch Biochem Biophys 302:118-127.
135. Lovell MA, Ehmann WD, Mattson MP, and Markesbery WR (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18:457-461.
136. Lovell MA, Xie C, and Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187-194.
137. Maas JW, Benensohn H, and Landis DH (1970) A kinetic study of the disposition of circulating norepinephrine in normal male subjects. J Pharmacol Exp Ther 174:381-387.
138. Mackenzie PI, Walter BK, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
139. MacKerell AD Jr, Blatter EE, and Pietruszko R (1986) Human aldehyde dehydrogenase: kinetic identification of the isozyme for which biogenic aldehydes and acetaldehyde compete. Alcohol Clin Exp Res 10:266-270.
140. MacKerell AD Jr and Pietruszko R (1987) Chemical modification of human aldehyde dehydrogenase by physiological substrate. Biochim Biophys Acta 911:306-317.
141. Maki PA and Sladek NE (1993) Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide. Biochem Pharmacol 45:231-239.
142. Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, and Youdim MB (2005) Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann NY Acad Sci 1053:356-375.
143. Mandelkow EM, Stamer K, Vogel R, Thies E, and Mandelkow E (2003) Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24:1079-1085.
144. Mardh G and Anggard E (1984) Norepinephrine metabolism in man using deuterium labelling: origin of 4-hydroxy-3-methoxymandelic acid. J Neurochem 42:43-46.
145. Mardh G, Luehr CA, and Vallee BL (1985) Human class I alcohol dehydrogenases catalyze the oxidation of glycols in the metabolism of norepinephrine. Proc Natl Acad Sci USA 82:4979-4982.
146. Mardh G, Sjoquist B, and Anggard E (1983) Norepinephrine metabolism in humans studied by deuterium labelling: turnover of 4-hydroxy-3- methoxyphenylglycol. J Neurochem 41:246-250.
147. Mardh G and Vallee BL (1986) Human class I alcohol dehydrogenases catalyze the interconversion of alcohols and aldehydes in the metabolism of dopamine. Biochemistry 25:7279-7282.
148. Maring JA, Deitrich RA, and Little R (1985) Partial purification and properties of human brain aldehyde dehydrogenases. J Neurochem 45:1903-1910.
149. Martinez SE, Vaglenova J, Sabria J, Martinez MC, Farres J, and Pares X (2001) Distribution of alcohol dehydrogenase mRNA in the rat central nervous system: consequences for brain ethanol and retinoid metabolism. Eur J Biochem 268:5045-5056.
150. Maruyama W, Narabayashi H, Dostert P, and Naoi M (1996) Stereospecific occurrence of a parkinsonism-inducing catechol isoquinoline, n-methyl(R)salsolinol, in the human intraventricular fluid. J Neural Transm 103:1069-1076.
151. Mattammal MB, Haring JH, Chung HD, Raghu G, and Strong R (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 4:271-281.
152. McNaught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, and Marsden CD (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol 56:921-933.
153. McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, and Marsden CD (1995) Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Biochem Pharmacol 50:1903-1911.
154. Messiha FS (1978) Voluntary drinking of ethanol by the rat: biogenic amines and possible underlying mechanism. Pharmacol Biochem Behav 9:379-384.
155. Messiha FS (1988) Tourette's medications: effect on minor oxidative and reductive pathways of biogenic amines. Neurosci Biobehav Rev 12:215-218.
156. Messiha FS, Striegler RL, and Sproat HF (1983) Modification of mouse liver alcohol and aldehyde-dehydrogenase by chlorpromazine. Drug Chem Toxicol 6:409-419.
157. Meyer MJ, Mosely DE, Amarnath V and Picklo MJ Sr (2004) Metabolism of 4-hydroxy-trans-2-nonenal by central nervous system mitochondria is dependent on age and NAD+ availability. Chem Res Toxicol 17:1272-1279.
158. Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, Willemsen MA, Omran H, Tacke U, Uhlenberg B, et al. (2006) Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 12:307-309.
159. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
160. Mitchell DY and Petersen DR (1988) Inhibition of rat liver aldehyde dehydrogenases by acrolein. Drug Metab Dispos 16:37-42.
161. Mitchell DY and Petersen DR (1991) Inhibition of rat hepatic mitochondrial aldehyde dehydrogenase-mediated acetaldehyde oxidation by trans-4-hydroxy-2-nonenal. Hepatology 13:728-734.
162. Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, and Woitalla D (2006) Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 21:332-336.
163. Muto M, Hitomi Y, Ohtsu A, Ebihara S, Yoshida S, and Esumi H (2000) Association of aldehyde dehydrogenase 2 gene polymorphism with multiple oesophageal dysplasia in head and neck cancer patients. Gut 47:256-261.
164. Nadkarni DV and Sayre LM (1995) structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 8:284-291.
165. Nagar S and Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25:1659-1672.
166. Nair V, Cooper CS, Vietti DE, and Turner GA (1986) The chemistry of lipid peroxidation metabolites: crosslinking reactions of malondialdehyde. Lipids 21:6-10.
167. Narayanan J, Hayakawa Y, Fan J, and Kirk KL (2003) Convenient syntheses of biogenic aldehydes, 3,4-dihydroxyphenylacetaldehyde and 3,4- dihydroxyphenylglycolaldehyde. Bioorg Chem 31:191-197.
168. Nestler EJ, Hyman SE, and Malenka RC (2001) Molecular Neuropharmacology: a Foundation for Clinical Neuroscience. McGraw Hill, New York.
169. Niederreither K, Fraulob V, Garnier JM, Chambon P, and Dolle P (2002) Differential expression of retinoic acid-synthesizing (RALDH) enzymes during fetal development and organ differentiation in the mouse. Mech Dev 110:165-171.
170. Niederreither K, Subbarayan V, Dolle P, and Chambon P (1999) Embryonic retinoic acid synthesis is essential for early mouse post-implantation development. Nat Genet 21:444-448.
171. Nilsson GE (1988) Aldehyde dehydrogenase activity in brain and liver of the rainbow trout (Salmo gairdneri Richardson). J Exp Zool 247:189-197.
172. O'Brien PJ, Siraki AG, and Shangari N (2005) Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 35:609-662.
173. Obata T (2002) Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 109:1159-1180.
174. Ohta S and Ohsawa I (2006) Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J Alzheimers Dis 9:155-166.
175. Okada T, Shimada S, Sato K, Kotake Y, Kawai H, Ohta S, Tohyama M, and Nishimura T (1998) Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells. Neurosci Res 30:87-90.
176. Olanow CW and Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
177. Oreland L and Gottfries CG (1986) Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 10:533-540.
178. Orrenius S and Nicotera P (1994) The calcium ion and cell death. J Neural Transm Suppl 43:1-11.
179. Packer MA, Scarlett JL, Martin SW, and Murphy MP (1997) Induction of the mitochondrial permeability transition by peroxynitrite. Biochem Soc Trans 25:909-914.
180. Palmer MR, Tottmar O, and Deitrich RA (1986) Electrophysiological effects of monoamine-derived aldehydes on single neurons in neocortex and cerebellum in rats. Alcohol Clin Exp Res 10:682-685.
181. Pappa A, Brown D, Koutalos Y, DeGregori J, White C, and Vasiliou V (2005) Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem 280:27998-28006.
182. Pearl PL, Gibson KM, Acosta MT, Vezina LG, Theodore WH, Rogawski MA, Novotny EJ, Gropman A, Conry JA, Berry GT, et al. (2003) Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 60:1413-1417.
183. Petersen DR (1985) Aldehyde dehydrogenase and aldehyde reductase in isolated bovine brain microvessels. Alcohol 2:79-83.
184. Pettersson H and Tottmar O (1982) Aldehyde dehydrogenases in rat brain. subcellular distribution and properties. J Neurochem 38:477-487.
185. Piao YS, Wakabayashi K, Hayashi S, Yoshimoto M, and Takahashi H (2000) Aggregation of α-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Clin Neuropathol 19:163-169.
186. Pietruszko R, Meier J, Major LF, Saini N, Manz H, and Hawley RJ (1984) Human brain: aldehyde dehydrogenase activity and isozyme distribution in different areas. Alcohol 1:363-367.
187. Plecko B, Paul K, Paschke E, Stoeckler-Ipsiroglu S, Struys E, Jakobs C, Hartmann H, Luecke T, di CM, Korenke C, et al. (2006) Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) Gene. Hum Mutat 28:10-26
188. Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 21:49-98.
189. Przedborski S and Ischiropoulos H (2005) Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 7:685-693.
190. Raskin NH and Sokoloff L (1972) Enzymes catalysing ethanol metabolism in neural and somatic tissues of the rat. J Neurochem 19:273-282.
191. Reith ME, Xu C, and Chen NH (1997) Pharmacology and regulation of the neuronal dopamine transporter. Eur J Pharmacol 324:1-10.
192. Ren S, Kalhorn TF, and Slattery JT (1999) Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein. Drug Metab Dispos 27:133-137.
193. Renson J, Weissbach H, and Udenfriend S (1964) Studies on the biological activities of the aldehydes derived from norepinephrine, serotonin, tryptamine and histamine. J Pharmacol Exp Ther 143:326-331.
194. Richter D (1937) Adrenaline and amine oxidase. Biochem J 31:2022-2028.
195. Rickert WS, Robinson JC, and Young JC (1980) Estimating the hazards of "less hazardous" cigarettes. i. tar, nicotine, carbon monoxide, acrolein, hydrogen cyanide, and total aldehyde deliveries of Canadian cigarettes. J Toxicol Environ Health 6:351-365.
196. Rivett AJ, Eddy BJ, and Roth JA (1982) Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain. J Neurochem 39:1009-1016.
197. Rivett AJ, Francis A, and Roth JA (1983) Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain. J Neurochem 40:215-219.
198. Rizzo WB and Carney G (2005) Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum Mutat 26:1-10.
199. Robert PH, Verhey FR, Byrne EJ, Hurt C, De Deyn PP, Nobili F, Riello R, Rodriguez G, Frisoni GB, Tsolaki M, et al. (2005) Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects: consensus paper of the European Alzheimer Disease Consortium. Eur Psychiatry 20:490-496.
200. Robinson BH (1998) Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. Biochim Biophys Acta 1364:271-286.
201. Roe CR, Struys E, Kok RM, Roe DS, Harris RA, and Jakobs C (1998) Methylmalonic semialdehyde dehydrogenase deficiency: psychomotor delay and methylmalonic aciduria without metabolic decompensation. Mol Genet Metab 65:35-43.
202. Ryzlak MT and Pietruszko R (1987) Purification and characterization of aldehyde dehydrogenase from human brain. Arch Biochem Biophys 255:409-418.
203. Ryzlak MT and Pietruszko R (1989) Human brain glyceraldehyde-3-phosphate dehydrogenase, succinic semialdehyde dehydrogenase and aldehyde dehydrogenase isozymes: substrate specificity and sensitivity to disulfiram. Alcohol Clin Exp Res 13:755-761.
204. Sabelli HC, Giardina WJ, Alivisatos SG, Seth PK, and Ungar F (1969) Indoleacetaldehydes: serotonin-like effects on the central nervous system. Nature (Lond) 223:73-74.
205. Sandler M, Carter SB, Hunter KR, and Stern GM (1973) Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man. Nature (Lond) 241:439-443.
206. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222.
207. Sayre LM, Smith MA, and Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8:721-738.
208. Scarlett JL and Murphy MP (1997) Release of apoptogenic proteins from the mitochondrial intermembrane space during the mitochondrial permeability transition. FEBS Lett 418:282-286.
209. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827.
210. Schauenstein E, Esterbauer H, and Zollner H (1977) Aldehydes in Biological Systems: Their Natural Occurrence and Biological Activities. Pion, London.
211. Schaur RJ (2003) Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol Aspects Med 24:149-159.
212. Schnaitman C, Erwin VG, and Greenawalt JW (1967) The submitochondrial localization of monoamine oxidase: an enzymatic marker for the outer membrane of rat liver mitochondria. J Cell Biol 32:719-735.
213. Seaton TA, Cooper JM, and Schapira AH (1997) Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 777:110-118.
214. Shen ML, Johnson KL, Mays DC, Lipsky JJ, and Naylor S (2001) Determination of in vivo adducts of disulfiram with mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 61:537-545.
215. Siegenthaler G, Saurat JH, and Ponec M (1990) Retinol and retinal metabolism. relationship to the state of differentiation of cultured human keratinocytes. Biochem J 268:371-378.
216. Sladek NE, Manthey CL, Maki PA, Zhang Z, and Landkamer GJ (1989) Xenobiotic oxidation catalyzed by aldehyde dehydrogenases. Drug Metab Rev 20:697-720.
217. Stewart MJ, Malek K, Xiao Q, Dipple KM, and Crabb DW (1995) The novel aldehyde dehydrogenase gene, ALDH5, encodes an active aldehyde dehydrogenase enzyme. Biochem Biophys Res Commun 211:144-151.
218. Storch A, Ott S, Hwang YI, Ortmann R, Hein A, Frenzel S, Matsubara K, Ohta S, Wolf HU, and Schwarz J (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 63:909-920.
219. Storch A and Schwarz J (2000) The dopamine transporter: involvement in selective dopaminergic neurodegeneration, in Neurotoxic Factors in Parkinson's Disease and Related Disorders (Storch A and Collins MA eds) pp 17-40, Kluwer Academic Publishers, New York.
220. Sun AY, Ingelman-Sundberg M, Neve E, Matsumoto H, Nishitani Y, Minowa Y, Fukui Y, Bailey SM, Patel VB, Cunningham CC, et al. (2001) Ethanol and oxidative stress. Alcohol Clin Exp Res 25:237S-243S.
221. Sun X, Jia Y, Zhang X, Xu Q, Shen Y, and Li Y (2005) Multi-locus association study of schizophrenia susceptibility genes with a posterior probability method. Sci China C Life Sci 48:263-269.
222. Suzuki K, Mizuno Y, and Yoshida M (1990) Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain. Neurochem Res 15:705-710.
223. Svensson S, Some M, Lundsjo A, Helander A, Cronholm T, and Hoog JO (1999) Activities of human alcohol dehydrogenases in the metabolic pathways of ethanol and serotonin. Eur J Biochem 262:324-329.
224. Tabakman R, Lecht S, and Lazarovici P (2004) Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays 26:80-90.
225. Tabakoff B (1974) Inhibition of sodium, potassium, and magnesium activated ATPases by acetaldehyde and "biogenic" aldehydes. Res Commun Chem Pathol Pharmacol 7:621-624.
226. Tabakoff B, Anderson R, and Alivisatos SG (1973) Enzymatic reduction of "biogenic" aldehydes in brain. Mol Pharmacol 9:428-437.
227. Tabakoff B and Erwin VG (1970) Purification and characterization of a reduced nicotinamide adenine dinucleotide phosphate-linked aldehyde reductase from brain. J Biol Chem 245:3263-3268.
228. Tabakoff B and Gelpke CC (1975) Alcohol and aldehyde metabolism in brain. Adv Exp Med Biol 56:141-164.
229. Tank AW and Weiner H (1979) Ethanol-induced alteration of dopamine metabolism in rat liver. Biochem Pharmacol 28:3139-3147.
230. Tank AW, Weiner H, and Thurman JA (1981) Enzymology and subcellular localization of aldehyde oxidation in rat liver: oxidation of 3,4-dihydroxyphenylacetaldehyde derived from dopamine to 3,4- dihydroxyphenylacetic acid. Biochem Pharmacol 30:3265-3275.
231. Tipton KF, Houslay MD, and Turner AJ (1977) Metabolism of aldehydes in brain. Essays Neurochem Neuropharmacol 1:103-138.
232. Towell JF III and Wang RI (1987) Hydrogen peroxide-induced glutathione depletion and aldehyde dehydrogenase inhibition in erythrocytes. Biochem Pharmacol 36:2087-2093.
233. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
234. Tuma DJ, Donohue TM Jr, Medina VA, and Sorrell MF (1984) Enhancement of acetaldehyde-protein adduct formation by L-ascorbate. Arch Biochem Biophys 234:377-381.
235. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, and Allsop D (2001) α-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 30:1163-1170.
236. Tyce GM, Hunter LW, Ward LE, and Rorie DK (1995) Effluxes of 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylglycol, and norepinephrine from four blooimulation. J Neurochem 64:833-841.
237. Ueshima Y, Matsuda Y, Tsutsumi M, and Takada A (1993) Role of the aldehyde dehydrogenase-1 isozyme in the metabolism of acetaldehyde. Alcohol Alcohol Suppl 1B:15-19.
238. -1-pyrroline-5-carboxylic acid dehydrogenase deficiency in cultured skin fibroblasts and circulating lymphocytes. J Clin Investig 58:598-603.
239. Vasiliou V, Malamas M, and Marselos M (1986) The mechanism of alcohol intolerance produced by various therapeutic agents. Acta Pharmacol Toxicol (Copenh) 58:305-310.
240. Vasiliou V and Nebert DW (2005) Analysis and Update of the Human Aldehyde Dehydrogenase (ALDH) gene family. Hum Genomics 2:138-143.
241. Vasiliou V, Pappa A, and Estey T (2004) Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev 36:279-299.
242. Vasiliou V and Pappa A (2000) Polymorphisms of human aldehyde dehydrogenases: consequences for drug metabolism and disease. Pharmacology 61:192-198.
243. Veronese ME, Burgess W, Zhu X, and McManus ME (1994) Functional Characterization of Two Human Sulphotransferase cDNAs that encode monoamine- and phenol-sulphating forms of phenol sulphotransferase: substrate kinetics, thermalstability and inhibitor-sensitivity studies. Biochem J 302 (Pt 2):497-502.
244. Waldmeier PC, Delini-Stula A, and Maitre L (1976) Preferential deamination of dopamine by an a type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 292:9-14.
245. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science (Wash DC) 283:1482-1488.
246. Weiner H and Ardelt B (1984) Distribution and properties of aldehyde dehydrogenase in regions of rat brain. J Neurochem 42:109-115.
247. Wermuth B (1985) Aldo-keto reductases, in Enzymology of Carbonyl Metabolism 2: Aldehyde Dehydrogenase, Aldo Keto Reductase and Alcohol Dehydrogenase (Weiner H and Wermuth B eds) pp 209-230, Alan R. Liss, New York.
248. Westlund KN, Denney RM, Kochersperger LM, Rose RM, and Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science (Wash DC) 230:181-183.
249. Westlund KN, Krakower TJ, Kwan SW, and Abell CW (1993) Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 612:221-230.
250. Willemsen MA, IJlst L, Steijlen PM, Rotteveel JJ, de Jong JG, van Domburg PH, Mayatepek E, Gabreels FJ, and Wanders RJ (2001) Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome. Brain 124:1426-1437.
251. Williams L III, Evans PE, and Bowers WS (2001) Defensive chemistry of an aposematic bug, Pachycoris stallii Uhler and volatile compounds of its host plant Croton californicus Muell.-Arg. J Chem Ecol 27:203-216.
252. Wirth HP and Wermuth B (1985) Immunohistochemical localisation of aldehyde and aldose reductase in human tissues. Prog Clin Biol Res 174:231-239.
253. Xu Q, Jia YB, Zhang BY, Zou K, Tao YB, Wang YP, Qiang BQ, Wu GY, Shen Y, Ji HK, et al. (2004) Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: a novel strategy for complex disorders. Mol Psychiatry 9:510-521.
254. Yamanaka Y, Walsh MJ, and Davis VE (1970) Salsolinol, an alkaloid derivative of dopamine formed in vitro during alcohol metabolism. Nature (Lond) 227:1143-1144.
255. Yokoyama A, Muramatsu T, Ohmori T, Makuuchi H, Higuchi S, Matsushita S, Yoshino K, Maruyama K, Nakano M, and Ishii H (1996) Multiple primary esophageal and concurrent upper aerodigestive tract cancer and the aldehyde dehydrogenase-2 genotype of Japanese alcoholics. Cancer 77:1986-1990.
256. Yokoyama A, Muramatsu T, Omori T, Yokoyama T, Matsushita S, Higuchi S, Maruyama K, and Ishii H (2001) Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. Carcinogenesis 22:433-439.
257. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, and Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93:2696-2701.
258. Yoshida A, Huang IY, and Ikawa M (1984) Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci USA 81:258-261.
259. Youdim MB, Edmondson D, and Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309.
260. Younkin SG, Goodridge B, Katz J, Lockett G, Nafziger D, Usiak MF, and Younkin LH (1986) Molecular forms of acetylcholinesterases in Alzheimer's disease. Fed Proc 45:2982-2988.
261. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173.
262. Zimatkin SM and Karpuk Y (1996) Regional and cellular distribution of mitochondrial high-affinity aldehyde dehydrogenase in the rat brain (immunocytochemical investigation). Neurosci Behav Physiol 26:225-230.